Q. Dallas-yang

发表

FGF21 Analogs of Sustained Action Enabled by Orthogonal Biosynthesis Demonstrate Enhanced Antidiabetic Pharmacology in Rodents

Margaret S. Wu, D. Zaller, Thea C. Norman, 2012, Diabetes.

Rosiglitazone, an agonist of peroxisome-proliferator-activated receptor gamma (PPARgamma), decreases inhibitory serine phosphorylation of IRS1 in vitro and in vivo.

S. Biswas, Bei B. Zhang, Zhihua Li, 2004, The Biochemical journal.

Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1.

Margaret S. Wu, T. Doebber, D. Szalkowski, 2005, The Journal of clinical investigation.

Development of a novel GLUT4 translocation assay for identifying potential novel therapeutic targets for insulin sensitization.

M. Ferrer, J. Berger, F. Santini, 2009, The Biochemical journal.

Rosiglitazone, an agonist of peroxisome-proliferator-activated receptor γ (PPAR γ ), decreases inhibitory serine phosphorylation of IRS1 invitro and invivo

Bei B. Zhang, Li Zhihua, Q. Dallas-yang, 2003 .

Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists.

V. Ding, S. Qureshi, K. Chapman, 2005, Bioorganic & medicinal chemistry letters.

Salicylic Acid Reverses Phorbol 12-Myristate-13-Acetate (PMA)- and Tumor Necrosis Factor α (TNFα)-induced Insulin Receptor Substrate 1 (IRS1) Serine 307 Phosphorylation and Insulin Resistance in Human Embryonic Kidney 293 (HEK293) Cells*

D. Moller, Bei B. Zhang, Franklin Liu, 2003, The Journal of Biological Chemistry.

Discovery of potent, orally active benzimidazole glucagon receptor antagonists.

V. Ding, S. Qureshi, D. Szalkowski, 2008, Bioorganic & medicinal chemistry letters.

FGF21 suppresses hepatic glucose production through the activation of atypical protein kinase Cι/λ.

Yun-ping Zhou, J. Berger, Yuli Chen, 2013, European journal of pharmacology.

Anti-Diabetic Efficacy and Impact on Amino Acid Metabolism of GRA1, a Novel Small-Molecule Glucagon Receptor Antagonist

Margaret S. Wu, S. Qureshi, J. Mu, 2012, PloS one.

Detection of Glucagon-Dependent GTPγS Binding in High-Throughput Format

S. Qureshi, Bei B. Zhang, Q. Dallas-yang, 2002 .

Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists.

J. Fenyk-Melody, S. Qureshi, D. Szalkowski, 2004, European journal of pharmacology.

Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes.

S. Qureshi, S. Xu, Bei B. Zhang, 2012, Journal of medicinal chemistry.

Evidence that inhibition of insulin receptor signaling activity by PC-1/ENPP1 is dependent on its enzyme activity.

I. Wang, J. Berger, P. Lu, 2009, European Journal of Pharmacology.

Suppression of PC-1/ENPP-1 expression improves insulin sensitivity in vitro and in vivo.

Margaret S. Wu, I. Wang, J. Berger, 2009, European journal of pharmacology.

Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice

S. Qureshi, G. Jiang, J. Mu, 2011, Diabetologia.

Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core.

V. Ding, S. Qureshi, K. Chapman, 2011, Bioorganic & medicinal chemistry letters.

Discovery of N-aryl-2-acylindole human glucagon receptor antagonists.

V. Ding, S. Qureshi, D. Szalkowski, 2011, Bioorganic & medicinal chemistry letters.

Discovery of cyclic guanidines as potent, orally active, human glucagon receptor antagonists.

V. Ding, S. Qureshi, D. Szalkowski, 2011, Bioorganic & medicinal chemistry letters.

MODY1 mutation Q268X in hepatocyte nuclear factor 4alpha allows for dimerization in solution but causes abnormal subcellular localization.

F. Sladek, Q. Dallas-yang, L. Nepomuceno, 1998, Diabetes.

Analysis of protein dimerization and ligand binding of orphan receptor HNF4alpha.

F. Cohen, A. Bogan, F. Sladek, 2000, Journal of molecular biology.

Avoiding false positives in colony PCR.

F. Sladek, Q. Dallas-yang, G. Jiang, 1998, BioTechniques.

Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPARgamma agonists.

Margaret S. Wu, J. Berger, D. Moller, 2002, Diabetes.

A glucose-responsive insulin therapy protects animals against hypoglycemia.

Margaret S. Wu, M. Erion, D. Kelley, 2018, JCI Insight.

Downstream Signaling Pathways in Mouse Adipose Tissues Following Acute In Vivo Administration of Fibroblast Growth Factor 21

Margaret S. Wu, R. Hendrickson, C. Paweletz, 2013, PloS one.

Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1.

Margaret S. Wu, T. Doebber, D. Szalkowski, 2005, The Journal of clinical investigation.

A glucose-responsive insulin therapy protects animals against hypoglycemia.

Margaret S. Wu, M. Erion, D. Kelley, 2018, JCI insight.

Evidence that inhibition of insulin receptor signaling activity by PC-1/ENPP1 is dependent on its enzyme activity.

I. Wang, J. Berger, P. Lu, 2009, European journal of pharmacology.